Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -36.19% is 77% above its 3-year average of -157.70%, near the high end of its 3-year range (-564.60%–-11.95%).
64.65% below its 12-month average of -21.98%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.82%.
RETURN ON ASSETS (ROA)
-36.19%
RETURN ON ASSETS (ROA) AVG TTM
-21.98%
RETURN ON ASSETS (ROA) AVG 3Y
-157.70%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-64.65%
CURRENT VS 3Y AVG
+77.05%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.27%
median of 386 covered companies
CURRENT VS SECTOR MEDIAN
-55.49%
vs the sector median at left
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
Return on Assets (ROA)
-36.19%
TTM Avg
-21.98%
3Y Avg
-157.70%
5Y Avg
N/A
Market Cap
$1.12B
Return on Assets (ROA)
-3.46%
TTM Avg
-0.37%
3Y Avg
-7.11%
5Y Avg
-6.26%
Market Cap
$1.12B
Return on Assets (ROA)
4.50%
TTM Avg
8.06%
3Y Avg
9.38%
5Y Avg
7.83%
Market Cap
$1.16B
Return on Assets (ROA)
0.69%
TTM Avg
1.67%
3Y Avg
0.18%
5Y Avg
-3.47%
Market Cap
$1.20B
Return on Assets (ROA)
-57.23%
TTM Avg
-57.23%
3Y Avg
-57.23%
5Y Avg
-57.23%
Market Cap
$1.21B
Return on Assets (ROA)
5.91%
TTM Avg
1.36%
3Y Avg
-4.42%
5Y Avg
-8.30%
Market Cap
$1.05B
Return on Assets (ROA)
-6.43%
TTM Avg
-17.46%
3Y Avg
-82.63%
5Y Avg
-55.94%
Market Cap
$1.24B
Return on Assets (ROA)
-48.35%
TTM Avg
-102.84%
3Y Avg
-97.55%
5Y Avg
-75.48%
Market Cap
$989.05M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | -36.19% | -21.98% | -157.70% | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | -3.46% | -0.37% | -7.11% | -6.26% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 4.50% | 8.06% | 9.38% | 7.83% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 0.69% | 1.67% | 0.18% | -3.47% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | -57.23% | -57.23% | -57.23% | -57.23% |
| Cronos Group Inc. (CRON)vs › | $1.21B | 5.91% | 1.36% | -4.42% | -8.30% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | -6.43% | -17.46% | -82.63% | -55.94% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | -48.35% | -102.84% | -97.55% | -75.48% |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | -13.12% | -18.77% | -18.48% | -18.48% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | -56.27% | -37.98% | -21.94% | -21.15% |
ROA
-36.2%
ROE
-39.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -32.01% |
| 2024-12-31 | -11.95% |
| 2023-12-31 | -22.22% |
| 2022-12-31 | -564.60% |
